Standigm Synthetic Research Center successfully accelerates drug discovery in its first year
Standigm, the workflow AI-driven drug discovery company, today announced the celebration of its Synthetic Research Center's first year. In the last 12 months, the company has collaborated with outside researchers to create hundreds of novel molecules that help speed drug discovery
Lab uniquely enables collaboration between chemical and AI researchers
SEOUL, South Korea, Nov. 16, 2022 /PRNewswire/ -- Standigm, the workflow AI-driven drug discovery company, today announced the celebration of its Synthetic Research Center's first year. In the last 12 months, the company has collaborated with outside researchers to create hundreds of novel molecules that help speed drug discovery.
Standigm's Synthetic Research Center was originally established to help the company attract top medicinal chemists, reduce drug discovery risks and manage its chemical library efficiently. It is located inside SK Chemicals' headquarters in Seoul. SK Chemicals is Standigm's lead investor and a research partner.
"Having a synthetic lab is essential as many medical chemists regard themselves as bench scientists and don't like desktop-only jobs," said Hanjo Kim, SVP of global strategy and head of medicinal chemistry at Standigm. "Synthesizing molecules is a time-determining step in early drug discovery projects and the externalization of this essential function is a significant risk for any drug discovery company."
